Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Saved in:
Bibliographic Details
Title: Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Authors: Shadman M; Fred Hutchinson Cancer Center, Seattle, WA, USA., Salkar M; AbbVie, North Chicago, IL, USA., Srivastava B; AbbVie, North Chicago, IL, USA., Karve S; AbbVie, North Chicago, IL, USA., Emond B; Analysis Group, Inc., Montréal, Canada., Gogna P; Analysis Group, Inc., Montréal, Canada., Manceur AM; Analysis Group, Inc., Montréal, Canada., Lafeuille MH; Analysis Group, Inc., Montréal, Canada., Rava A; Genesis Research Group, Hoboken, NJ, USA., Sun H; Genesis Research Group, Hoboken, NJ, USA., Howarth A; Genesis Research Group, Hoboken, NJ, USA., Tomicki S; Genesis Research Group, Hoboken, NJ, USA., Agatep B; Inovalon, Bowie, MD, USA., Jones B; Inovalon, Bowie, MD, USA., Franceschini E; AbbVie, North Chicago, IL, USA., Saifan C; AbbVie, North Chicago, IL, USA., Bacchus S; AbbVie, North Chicago, IL, USA., Roeker L; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Stephens DM; Division of Hematology, University of North Carolina, Chapel Hill, NC, USA.
Source: Leukemia & lymphoma [Leuk Lymphoma] 2025 Jan; Vol. 66 (1), pp. 44-53. Date of Electronic Publication: 2024 Oct 01.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1029-2403
DOI:10.1080/10428194.2024.2402814